ArticleJournal of inflammation research2025
Impact of Beta-Blockers on Pneumonia, Mortality and Functional Outcomes of Patients with Intracerebral Hemorrhage-A Retrospective Multicenter Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Given the current lack of research on the impact of beta-blockers (BB) on clinical outcomes in patients with intracerebral hemorrhage (ICH). This study aimed to evaluate the effect of BB on pneumonia, functional outcomes, and mortality in adult patients with primary ICH. Patients and Methods: This was a retrospective study of a registry cohort of patients with ICH from 13 stroke centers in Beijing, China. Patients aged 18 years or older with first-time primary ICH admitted within 72 h after onset were included. Main exclusion criteria including previous ICH, previous mRS≥3, primary intraventricular hemorrhage, missing of baseline data or lost of follow-up. BB group was defined as any use of beta-blockers pre-existing or initiated after onset of ICH, those without any use of beta-blockers were defined as non-BB group. The clinical outcomes were in-hospital pneumonia, mortality and functional outcome (favorable outcome defined as a modified Rankin Score of 0-3) at 90 d. Results: The study included 947 patients (657 males [69.38%]; mean [standard deviation] age, 57.67 [13.68] years). Two hundred and thirty of 809 patients (28.43%) in the non-BB group and 64 of 138 patients in the BB group were diagnosed with pneumonia (46.38%). Multivariate analysis confirmed that patients in the BB group were likely to have an increased risk of pneumonia after adjusting for confounders (odds ratio [OR], 1.806; 95% confidence interval [CI]:1.139-2.862; P=0.0119). No statistical difference was observed in the proportion of favorable outcome (P=0.9289) or mortality (P=0.2120) at 90 d between the two groups. Conclusion: The results of this cohort study suggest that any use of BB is associated with an increased risk of pneumonia post-ICH. Randomized clinical trials are needed to evaluate the effects of non-selective BB on the prevention of pneumonia post-ICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.